Skip to main content
World Journal of Gastrointestinal Surgery logoLink to World Journal of Gastrointestinal Surgery
. 2024 Apr 27;16(4):1121–1129. doi: 10.4240/wjgs.v16.i4.1121

Incidence of surgical site infection in minimally invasive colorectal surgery

Lu-Ting Ni 1, Ru Zhao 2, Yi-Ru Ye 3, Yi-Ming Ouyang 4, Xin Chen 5
PMCID: PMC11056659  PMID: 38690046

Abstract

BACKGROUND

Surgical site infection (SSI) is a common complication of colorectal surgery. Minimally invasive surgery notably reduces the incidence of SSI. This study aimed to compare the incidences of SSI after robot-assisted colorectal surgery (RACS) vs that after laparoscopic assisted colorectal surgery (LACS) and to analyze associated risk factors for SSI in minimally invasive colorectal surgery.

AIM

To compare the incidences of SSI after RACS and LACS, and to analyze the risk factors associated with SSI after minimally invasive colorectal surgery.

METHODS

Clinical data derived from patients who underwent minimally invasive colorectal surgery between October 2020 and October 2022 at the First Affiliated Hospital of Soochow University were collated. Differences in clinical characteristics and surgeryrelated information associated with RACS and LACS were compared, and possible risk factors for SSI were identified.

RESULTS

A total of 246 patients (112 LACS and 134 RACS) were included in the study. Fortythree (17.5%) developed SSI. The proportions of patients who developed SSI were similar in the two groups (17.9% vs 17.2%, P = 0.887). Diabetes mellitus, intraoperative blood loss ≥ 100 mL, and incision length were independent risk factors for SSI. Possible additional risk factors included neoadjuvant therapy, lesion site, and operation time.

CONCLUSION

There was no difference in SSI incidence in the RACS and LACS groups. Diabetes mellitus, intraoperative blood loss ≥ 100 mL, and incision length were independent risk factors for postoperative SSI.

Keywords: Colorectal surgery, Minimally invasive surgery, Surgical site infection


Core Tip: The application of robotic surgery in colorectal surgery is becoming increasingly widespread. While it brings convenience of operation, it is still unclear whether it increases the risk of surgical site infection (SSI). The current study compared the incidences of SSI in robot-assisted colorectal surgery and laparoscopic-assisted colorectal surgery, and analyzed potential risk factors associated with SSI after minimally invasive colorectal surgery, to provide guidance for clinical practice.

INTRODUCTION

According to World Health Organization (WHO) guidelines, surgical site infection (SSI) is defined as an infection that occurs within 30 d after an operation and involves the skin and subcutaneous tissue of the incision (superficial incisional) and/or the deep soft tissue (for example fascia and muscle) of the incision (deep incisional) and/or any part of the anatomy (for example organs and spaces) other than the incision that was opened or manipulated during an operation[1]. Common risk factors for SSI include preoperative diabetes mellitus, contaminative incision, excess subcutaneous fat, advanced age, obesity, and emergency surgery[2,3].

Colorectal surgical incision is a type II incision. Pathogens that often colonize the digestive tract may cause SSI. According to relevant studies, patients undergoing colorectal surgery are particularly at risk of SSI, with the infection rate as high as 26%[4,5]. Therefore, SSI is one of the most common early complications after colorectal surgery, which often leads to an increase in costs and hospitalization and even affects oncologic outcomes[6-8].

The application of robotic surgery is currently increasing, but it is expensive and involves issues such as installing and removing machines, resulting in longer surgery times. Robotic surgery brings convenience, but it is not clear whether it increases the risk of incision infections. The current study compared the incidences of SSI after robot-assisted colorectal surgery (RACS) and laparoscopic assisted colorectal surgery (LACS), and analyzed potential risk factors associated with SSI after minimally invasive colorectal surgery.

MATERIALS AND METHODS

Patient characteristics

This retrospective study included 246 patients who underwent minimally invasive colorectal surgery (LACS or RACS) at the General Surgery Department of the First Affiliated Hospital of Suzhou University from October 2020 to October 2022. The inclusion criteria were: (1) Patients scheduled to undergo elective radical surgery, and preoperative preparation was complete; (2) the minimally invasive surgery undergone was the first operation since admission; (3) age range 18-90 years; and (4) the operation was performed by the same general surgeon with experience in robotic surgery and laparoscopic surgery. The exclusion criteria were: (1) Patients who underwent open surgery or emergency surgery; (2) patients with active infection or a purulent cavity in the operation area before surgery; and (3) patients who were lost to follow-up.

According to existing guidelines, the patients all met the scope of minimally invasive colorectal surgery. The choice of surgical method was based on the patients’ wishes. The study was approved by the Ethics Committee of the First Affiliated Hospital of Soochow University. Written informed consent was obtained from all patients.

Age, gender, body mass index (BMI), American Society of Anesthesiologist (ASA) grade, history of past illness, pathology, and relevant laboratory examinations were reviewed via the electronic medical record information system. The operation data collected included operation time, operation site, anastomosis method, intraoperative blood loss, time of postoperative intake, and incision length.

All patients were administered cefazolin (1 g) or cefathiamidine (1 g) via intravenous drip 0.5-1.0 h before the operation. If the surgery time was > 3 h, additional cefazolin (1 g) or cefathiamidine (1 g) was administered during the operation. In patients with cephalosporin allergy, an intravenous drip of etimicin 0.1 g was used instead. Antibiotics were administered 12 h and 48 h after the operation.

The main outcome measure was the incidence of SSI within 30 d after surgery. SSI was diagnosed based on WHO guidelines. Observation index information was mainly obtained via telephone calls and outpatient follow-up.

Statistical analysis

All statistical analyses were performed using SPSS software (version 26.0). The twotailed t-test was used for continuous variables, unless the data were non-normally distributed. In such cases the Mann-Whitney U test was used to assess comparisons. The χ2 test or Fisher’s exact test were used for categorical variables, which were summarized as frequencies and percentages. All collected variables were analyzed using univariate logistic analysis, and those with P < 0.15 were selected for inclusion in multivariable logistic analysis. All statistical analyses were two-sided, and P < 0.05 was considered statistically significant.

RESULTS

Clinical characteristics and surgical results

A total of 246 patients were included in the study, 112 who underwent LACS and 134 who underwent RACS. The clinical characteristics of the patients are shown in Table 1. The age of the patients in the LACS and RACS groups was similar (64 years vs 66 years, P = 0.105), and most were male. Twenty-eight (11.4%) had a history of smoking, 97 (39.4%) had a history of hypertension, and 31 (12.6%) had diabetes mellitus. More patients in the LACS group received neoadjuvant therapy before surgery (9.8% vs 3.7%, P = 0.054) and there was more intraoperative blood loss in the LACS group (44.6% vs 14.2%, P < 0.001). The mean operation time was longer in the RACS group (281 min vs 243 min, P = 0.004). The anastomosis method was similar in the two groups. The incidences of SSI were similar in the two groups (17.9% vs 17.2%, P = 0.887), and the overall incidence of SSI was 17.5% (Table 2).

Table 1.

Clinical characteristics, n (%)


LACS (n = 112)
RACS (n = 134)
P value
Age (yr) 64 (56, 70) 66 (58, 72) 0.105
Sex 0.590
    Male 78 (69.6) 89 (66.4)
    Female 34 (30.4) 45 (33.6)
BMI 0.334
    < 24 76 (67.9) 83 (61.9)
    ≥ 24 36 (32.1) 51 (38.1)
Lesion site 0.925
    Colon 57 (50.9) 69 (51.5)
    Rectum 55 (49.1) 65 (48.5)
ASA 0.188
    Ⅰ–Ⅱ 98 (87.5) 109 (81.3)
    Ⅲ–Ⅳ 14 (12.5) 25 (18.7)
Hypertension 0.407
    No 71 (63.4) 78 (558.2)
    Yes 41 (36.6) 56 (41.8)
Diabetes mellitus 0.415
    No 100 (89.3) 115 (85.8)
    Yes 12 (10.7) 19 (14.2)
Hyperlipidemia 0.291
    No 79 (70.5) 86 (64.2)
    Yes 33 (29.5) 48 (35.8)
Smoking history 0.919
    No 99 (88.4) 119 (88.8)
    Yes 13 (11.6) 15 (11.2)
History of abdomen surgery 0.534
    No 84 (75.0) 105 (78.4)
    Yes 28 (25.0) 29 (21.6)
Previous operation except abdomen surgery 0.801
    No 82 (73.2) 100 (74.6)
    Yes 30 (26.8) 34 (25.4)
Tumor marker 0.730
    Normal 93 (83.0 109 (81.3)
    Abnormal 19 (17.0) 25 (18.7)
Liver function 0.599
    Normal 107 (95.5) 126 (94.0)
    Abnormal 5 (4.5) 8 (6.0)
Albumin 0.366
    ≥ 40 63 (56.3) 83 (61.9)
    < 40 49 (43.8) 51 (38.1)
Preoperative CRP 0.687
    Normal 82 (73.2) 95 (70.9)
    Abnormal 30 (26.8) 39 (29.1)
Uric acid 0.109
    Normal 98 (87.5) 107 (79.9)
    Abnormal 14 (12.5) 27 (20.1)
Recent weight loss 0.378
    No 85 (75.9) 95 (70.9)
    Yes 27 (24.1) 39 (29.1)
Neoadjuvant therapy 0.054
    No 101 (90.2) 129 (96.3)
    Yes 11 (9.8) 5 (3.7)

ASA: American Society of Anesthesiologists; BMI: Body mass index; CRP: Creactive protein; LACS: Laparoscopic-assisted colorectal surgery; RACS: Robot-assisted colorectal surgery.

Table 2.

Surgery results, n (%)


LACS (n = 112)
RACS (n = 134)
P value
Pathology
    Benign 49 (43.8) 47 (35.1) 0.165
    Malignant 63 (56.3) 87 (64.9)
Method of anastomosis 0.848
    Intracorporeal 63 (56.2) 77 (57.5)
    Extracorporeal 49 (43.8) 57 (42.5)
Incision length (66, 6) 6 (5, 6) 0.549
Intraoperative blood loss     < 0.001
    < 100 mL 62 (55.4) 115 (85.8)
    ≥ 100 mL 50 (44.6) 19 (14.2)
Operation time 243 (212, 305) 281 (239, 317) 0.004
Time of postoperative intake (d) 2 (2, 3) 2 (2, 3) 0.783
SSI 0.887
    No 92 (82.1) 111 (82.8)
    Yes 20 (17.9) 23 (17.2)

LACS: Laparoscopic-assisted colorectal surgery; RACS: Robot-assisted colorectal surgery; SSI: Surgical site infection.

SSI Risk factors

Demographic and operative information of the cohort by the occurrence or otherwise of SSI is shown in Table 3. In logistic analysis lesion site [odds ratio (OR) 1.996, 95% confidence interval (CI) 1.014-3.929, P = 0.045], diabetes mellitus (OR 3.749, 95%CI 1.656-8.484, P = 0.002), neoadjuvant therapy (OR 3.130, 95%CI 1.072-9.138, P = 0.037), incision length (OR 1.429, 95%CI 1.126-1.815, P = 0.003), intraoperative blood loss ≥ 100 mL (OR 3.082, 95%CI 1.562-6.084, P = 0.001), and long operation time (OR 1.005, 95%CI 1.001-1.009, P = 0.006) were predictors of SSI. There was no significant difference in the incidences of SSI in the LACS and RACS groups (OR 0.953, 95%CI 0.493-1.844, P = 0.887). Variables with P < 0.15 in the univariate analysis were then included in a multivariate analysis (Figure 1). Independent risk factors for SSI after minimally invasive colorectal surgery indicated in that analysis were diabetes mellitus (OR 4.660, 95%CI 1.663-13.056, P = 0.003), intraoperative blood loss ≥ 100 mL (OR 2.328, 95%CI 1.025-5.289, P = 0.044), and incision length (OR 1.405, 95%CI 1.059-1.864, P = 0.018).

Table 3.

Risk factors for the development of surgical site infection, n (%)


Non-SSI (n = 203)
SSI (n = 43)
OR
95%CI
P value
Sex
    Male 136 (76.0) 31 (72.1) Ref

    Female 6 (33.0) 12 (27.9) 0.786 0.380-1.627 0.516
Age 65 (57, 71) 64 (57, 72) 1.006 0.976-1.037 0.697
BMI
    < 24 134 (66.0)
25 (58.1) Ref
    ≥ 24 69 (34.0) 18 (41.9) 1.398 0.714-2.738 0.328
Pathology
    Benign 80 (39.4) 16 (37.2) Ref
    Malignant 123 (60.6) 27 (62.8) 1.098 0.556-2.165 0.788
Lesion site
    Colon 110 (54.2) 16 (37.2) Ref
    Rectum 93 (45.8) 27 (62.8) 1.996 1.014-3.929 0.045
ASA
    Ⅰ–Ⅱ 172 (84.7) 35 (81.4) Ref
    Ⅲ–Ⅳ 31 (15.3) 8 (18.6) 1.268 0.538-2.991 0.587
Hypertension
    No 125 (61.6) 24 (55.8) Ref
    Yes 78 (38.4) 19 (44.2) 1.269 0.652-2.467 0.483
Diabetes mellitus
    No 184 (90.6) 31 (72.1) Ref
    Yes 19 (9.4) 12 (27.9) 3.749 1.656-8.484 0.002
Hyperlipidemia
    No 140 (69.0) 25 (58.1) Ref
    Yes 63 (31.0) 18 (41.9) 1.600 0.815-3.142 0.172
Smoking history
No 178 (87.7) 40 (93.0) Ref
Yes 25 (12.3) 3 (7.0) 0.534 0.154-1.856 0.324
History of abdomen surgery
    No 160 (78.8) 29 (67.4) Ref
    Yes 43 (21.2) 14 (32.6) 1.796 0.873-3.695 0.111
Previous operation except abdomen surgery
    No 151 (74.4) 31 (72.1) Ref
    Yes 52 (25.6) 12 (27.9) 1.124 0.538-2.349 0.756
Tumor marker
    Normal 167 (82.3) 35 (81.4) Ref
Abnormal 36 (17.7) 8 (18.6) 1.060 0.454-2.477 0.892
Liver function
    Normal 194 (95.6) 39 (90.7) Ref
    Abnormal 9 (4.4) 4 (9.3) 2.211 0.648-7.541 0.205
Preoperative albumin
    ≥ 40 124 (61.1) 22 (51.2) Ref
    < 40 79 (38.9) 21 (48.8) 1.498 0.773-2.902 0.231
Uric acid
    Normal 166 (81.8) 39 (90.7) Ref
    Abnormal 37 (18.2) 4 (9.3) 0.460 0.155-1.367 0.162
Recent weight loss
    No 153 (75.4) 27 (62.8) Ref
    Yes 50 (24.6) 16 (37.2) 1.813 0.904-3.637 0.094
Neoadjuvant therapy
    No 193 (95.1) 37 (86.0) Ref
    Yes 10 (4.9) 6 (14.0) 3.130 1.072-9.138 0.037
Method of anastomosis
    Intracorporeal 120 (59.1) 20 (46.5) Ref
    Extracorporeal 83 (40.9) 23 (53.5) 1.663 0.858-3.221 0.132
Incision length 6 (5, 7) 6 (6, 6) 1.429 1.126-1.815 0.003
Intraoperative blood loss
    < 100 mL 155 (76.4) 22 (51.2) Ref
    ≥ 100 mL 48 (23.6) 21 (48.8) 3.082 1.562-6.084 0.001
Operation time 260 (215, 312) 301 (243, 334) 1.005 1.001-1.009 0.006
Time of postoperative intake (d) 2 (2, 3) 2 (2, 3) 1.241 0.737-2.091 0.416
Preoperative CRP
    Normal 147 (72.4) 30 (69.8) Ref
    Abnormal 56 (27.6) 13 (30.2) 1.137 0.554-2.337 0.726
Surgery approach
    LACS 92 (45.3) 20 (46.5) Ref
    RACS 111 (54.7) 23 (53.5) 0.953 0.493-1.844 0.887

ASA: American Society of Anesthesiologists; BMI: Body mass index; CRP: Creactive protein; LACS: Laparoscopic-assisted colorectal surgery; RACS: Robot-assisted colorectal surgery; SSI: Surgical site infection.

Figure 1.

Figure 1

Forest plot illustrating the results of multivariate analysis for risk factors of surgical site infection.

DISCUSSION

SSIs are a common complication of colorectal surgery. In previous studies the overall incidence of SSI after colorectal surgery has ranged from approximately 7% to 26%[4,5,9,10]. The high incidence and various adverse effects of SSI have attracted the attention of surgeons. With advances in minimally invasive surgery the incidence of SSI has decreased significantly. In an analysis of a large database in the United States, minimally invasive surgery was associated with a lower incidence of SSI after surgery than open surgery. This was verified at different surgical sites in another study based on the prospective database of the National Surgical Quality Improvement Program for major surgical procedures[11]. Compared with open surgery, laparoscopic surgery can result in a smaller incision length, clearer surgical vision, and a milder systemic inflammatory reaction, which helps to reduce the occurrence of SSI[12].

Since the launch of the da Vinci surgical robot in 2000, minimally invasive surgery has undergone significant changes. It was initially approved for use in general surgeries. Over the past 20 years robotic surgery has undergone further development, and its indications are expanding, covering all fields of abdominal gastrointestinal surgery. Robotic surgery systems can enable operators to obtain three-dimensional and more precise vision, and they can compensate for surgeons’ hand tremors, so that they can perform more complex surgical operations[13]. Many retrospective studies and metaanalyses have demonstrated the advantages of robotic surgery in the application of abdominal digestive surgery, such as reducing hospitalization times and intraoperative bleeding. However, few studies have compared the incidences of SSI after robotic and laparoscopic surgery[14-17].

The total incidence of SSI in the current study was 17.5%, which is within the range of previously reported incidences of SSI mentioned above. There was also no significant difference in the incidences of postoperative SSI in the LACS and RACS groups (P = 0.887). Robotic surgery does not seem to reduce the incidence of postoperative SSI. This may be due to the methods of anastomosis and specimen extraction in robotic surgery being similar to those used in laparoscopic-assisted surgery at present. In a sense, the advantage of robotic surgery lies in optimizing the surgeon’s senses and operability, and there is no significant advantage in terms of SSI.

The independent risk factors for SSI identified in the current study were diabetes mellitus (OR 4.660, 95%CI 1.663-13.056, P = 0.003), intraoperative blood loss ≥ 100 mL (OR 2.328, 95%CI 1.025-5.289, P = 0.044) and incision length (OR 1.405, 95%CI 1.059-1.864, P = 0.018), which was similar to the results of previous studies[18]. The occurrence of SSI in patients with diabetes mellitus may be due to the fact that hyperglycemia interferes with the normal metabolism of cells and produces excessive reactive oxygen species, leading to blocked blood circulation and reduced tissue perfusion. In addition, hyperglycemia can activate the inflammatory pathway, reduce immune function, facilitate the growth of bacteria, and prolong the healing time of the anastomosis. Increased intraoperative blood loss may lead to tissue hypoxia, and a longer incision may increase the risk of pathogen contamination. In the current study RACS had a longer mean operation time than LACS, but this did not lead to a significant difference in the incidence of SSI. There were no significant associations between SSI and BMI, smoking history, high ASA grade, or low albumin level in the present study.

The study had some limitations. It was retrospective, the sample size was relatively small, and there was some bias. There are also differences between colonic surgery and rectal surgery. Considering the fact that both the colon and the rectum belong to the digestive tract, they were included in the analysis and discussion; but this is another limitation of the study. Moreover, due to insufficient medical records there were few clinical indicators. A prospective study incorporating large samples, multiple centers, and multiple indicators could be conducted to verify the results of the current study.

CONCLUSION

In the present study there was no difference in SSI incidences after RACS and LACS. RACS involved less bleeding, but required longer operation times. In logistic regression analysis diabetes mellitus, intraoperative blood loss, and incision length were independent risk factors for SSI.

ACKNOWLEDGEMENTS

The authors sincerely thank the First Affiliated Hospital of Soochow University for the provision of clinical data, which enabled the research to be performed.

Footnotes

Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Soochow University.

Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.

Conflict-of-interest statement: The authors declare that there are no conflicts of interest pertaining to this article.

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review started: January 19, 2024

First decision: February 5, 2024

Article in press: March 25, 2024

Specialty type: Gastroenterology and hepatology

Country/Territory of origin: China

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Augustin G, Croatia; Shah OJ, India S-Editor: Qu XL L-Editor: A P-Editor: Xu ZH

Contributor Information

Lu-Ting Ni, Department of Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.

Ru Zhao, Department of Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.

Yi-Ru Ye, Department of Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.

Yi-Ming Ouyang, Department of Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.

Xin Chen, Department of Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China. chenxinfyy@sina.com.

Data sharing statement

The technical appendix, statistical code, and dataset are available from the corresponding author at chenxinfyy@sina.com.

References

  • 1. Global Guidelines for the Prevention of Surgical Site Infection. Geneva: World Health Organization; 2018. [PubMed] [Google Scholar]
  • 2.Teppa R, Sude NS, Karanam VPK, Mallipudi BVP. Relevance of Subcutaneous Fat Thickness as a Risk Factor for Surgical Site Infections in Abdominal Surgeries. Cureus. 2022;14:e20946. doi: 10.7759/cureus.20946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Alkaaki A, Al-Radi OO, Khoja A, Alnawawi A, Maghrabi A, Altaf A, Aljiffry M. Surgical site infection following abdominal surgery: a prospective cohort study. Can J Surg. 2019;62:111–117. doi: 10.1503/cjs.004818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bennett-Guerrero E, Pappas TN, Koltun WA, Fleshman JW, Lin M, Garg J, Mark DB, Marcet JE, Remzi FH, George VV, Newland K, Corey GR SWIPE 2 Trial Group. Gentamicin-collagen sponge for infection prophylaxis in colorectal surgery. N Engl J Med. 2010;363:1038–1049. doi: 10.1056/NEJMoa1000837. [DOI] [PubMed] [Google Scholar]
  • 5.Itani KM, Wilson SE, Awad SS, Jensen EH, Finn TS, Abramson MA. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med. 2006;355:2640–2651. doi: 10.1056/NEJMoa054408. [DOI] [PubMed] [Google Scholar]
  • 6.Sugamata N, Okuyama T, Takeshita E, Oi H, Hakozaki Y, Miyazaki S, Takada M, Mitsui T, Noro T, Yoshitomi H, Oya M. Surgical site infection after laparoscopic resection of colorectal cancer is associated with compromised long-term oncological outcome. World J Surg Oncol. 2022;20:111. doi: 10.1186/s12957-022-02578-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Katsumata K, Enomoto M, Ishizaki T, Fujita S, Kanemitsu Y, Ito M, Shiomi A, Komori K, Ohue M, Ota M, Akazai Y, Shiozawa M, Yamaguchi T, Bando H, Sekimoto M, Kobatake T, Machida R, Akasu T, Moriya Y Colorectal Cancer Study Group of Japan Clinical Oncology Group. Risk factors for surgical site infection and association of surgical site infection with survival of lower rectal cancer patients without clinical lateral pelvic lymph node metastasis (clinical Stage II/III): Analysis of data from JCOG0212. Clin Exp Metastasis. 2021;38:459–466. doi: 10.1007/s10585-021-10117-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Keenan JE, Speicher PJ, Thacker JK, Walter M, Kuchibhatla M, Mantyh CR. The preventive surgical site infection bundle in colorectal surgery: an effective approach to surgical site infection reduction and health care cost savings. JAMA Surg. 2014;149:1045–1052. doi: 10.1001/jamasurg.2014.346. [DOI] [PubMed] [Google Scholar]
  • 9.Koskenvuo L, Lehtonen T, Koskensalo S, Rasilainen S, Klintrup K, Ehrlich A, Pinta T, Scheinin T, Sallinen V. Mechanical and oral antibiotic bowel preparation versus no bowel preparation for elective colectomy (MOBILE): a multicentre, randomised, parallel, single-blinded trial. Lancet. 2019;394:840–848. doi: 10.1016/S0140-6736(19)31269-3. [DOI] [PubMed] [Google Scholar]
  • 10.Woodfield JC, Clifford K, Schmidt B, Turner GA, Amer MA, McCall JL. Strategies for Antibiotic Administration for Bowel Preparation Among Patients Undergoing Elective Colorectal Surgery: A Network Meta-analysis. JAMA Surg. 2022;157:34–41. doi: 10.1001/jamasurg.2021.5251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Gandaglia G, Ghani KR, Sood A, Meyers JR, Sammon JD, Schmid M, Varda B, Briganti A, Montorsi F, Sun M, Menon M, Kibel AS, Trinh QD. Effect of minimally invasive surgery on the risk for surgical site infections: results from the National Surgical Quality Improvement Program (NSQIP) Database. JAMA Surg. 2014;149:1039–1044. doi: 10.1001/jamasurg.2014.292. [DOI] [PubMed] [Google Scholar]
  • 12.Delgado S, Lacy AM, Filella X, Castells A, García-Valdecasas JC, Pique JM, Momblán D, Visa J. Acute phase response in laparoscopic and open colectomy in colon cancer: randomized study. Dis Colon Rectum. 2001;44:638–646. doi: 10.1007/BF02234558. [DOI] [PubMed] [Google Scholar]
  • 13.Krummel TM. Surgical simulation and virtual reality: the coming revolution. Ann Surg. 1998;228:635–637. doi: 10.1097/00000658-199811000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Fruscione M, Pickens R, Baker EH, Cochran A, Khan A, Ocuin L, Iannitti DA, Vrochides D, Martinie JB. Robotic-assisted versus laparoscopic major liver resection: analysis of outcomes from a single center. HPB (Oxford) 2019;21:906–911. doi: 10.1016/j.hpb.2018.11.011. [DOI] [PubMed] [Google Scholar]
  • 15.Chen K, Pan Y, Zhang B, Maher H, Wang XF, Cai XJ. Robotic versus laparoscopic Gastrectomy for gastric cancer: a systematic review and updated meta-analysis. BMC Surg. 2017;17:93. doi: 10.1186/s12893-017-0290-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Sheng S, Zhao T, Wang X. Comparison of robot-assisted surgery, laparoscopic-assisted surgery, and open surgery for the treatment of colorectal cancer: A network meta-analysis. Medicine (Baltimore) 2018;97:e11817. doi: 10.1097/MD.0000000000011817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Kamarajah SK, Sutandi N, Robinson SR, French JJ, White SA. Robotic versus conventional laparoscopic distal pancreatic resection: a systematic review and meta-analysis. HPB (Oxford) 2019;21:1107–1118. doi: 10.1016/j.hpb.2019.02.020. [DOI] [PubMed] [Google Scholar]
  • 18.Cai W, Wang L, Wang W, Zhou T. Systematic review and meta-analysis of the risk factors of surgical site infection in patients with colorectal cancer. Transl Cancer Res. 2022;11:857–871. doi: 10.21037/tcr-22-627. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The technical appendix, statistical code, and dataset are available from the corresponding author at chenxinfyy@sina.com.


Articles from World Journal of Gastrointestinal Surgery are provided here courtesy of Baishideng Publishing Group Inc

RESOURCES